Amisulpride Repurposed As Intravenous Anti-Emetic By Acacia
This article was originally published in The Pink Sheet Daily
Executive Summary
Acacia Pharma also recruits J P Morgan Cazenove to evaluate strategic options and market positioning of repurposed low-dose antipsychotic.
You may also be interested in...
Droperidol Gets Second-Line, Narrowed Indication Due To Arrhythmia Risk
Updated labeling for Akorn's Inapsine and droperidol generics restricts the drug to second-line use for a narrowed indication due to the risk of fatal cardiac arrhythmias
Pipeline Watch: Phase III Readouts in Wilson Disease, Parkinson's Disease And COVID-19
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
AZ's Rare Disease Unit Reports Positive Phase III Results For Copper-Binding ALXN1840
Alexion/AstraZeneca has announced positive top-line results from the Phase III study of ALXN1840 in patients with the rare genetic disorder, Wilson disease, including in patients already on standard-of-care therapies. The compound is ahead of two candidate gene therapies from other companies at early-stage clinical development.